Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report)’s share price gapped up before the market opened on Tuesday following a stronger than expected earnings report. The stock had previously closed ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

Beam expects that its cash, cash equivalents and marketable securities as of December 31, 2024, will enable the company to fund its anticipated ...

Full Year 2024 Results Key Financial Results Revenue: US$63.5m (down 83% from ...

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, February 25th.Analysts expect Beam Therapeutics to ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price target ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

In collaboration with Hitachi, the National Cancer Centre Singapore has introduced Proton Beam Therapy - a treatment designed to target tumours with precision while reducing the impact on healthy ...

Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial ofBEAM-101; Dosing of 30 Patients and Updated Data Expected by ...